GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases

Collaboration combines GentiBio's best-in-class engineered regulatory T cell platform with Bristol Myers Squibb's leadership in cell therapy and immunology drug development GentiBio to receive upfront cash payment, up to $1.9 billion in potential future... Biopharmaceuticals, Gastroenterology GentiBio , Bristol Myers Squibb, engineered Treg, inflammatory bowel diseases
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news